• Enesi Pharma and GeoVax to Collaborate on Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform

  2nd January 2019

  Potential for Addressing Multiple Infectious Disease Targets OXFORD, UK and ATLANTA, GA – 2 January 2019 – Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, and GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today a collaboration to develop solid-dose needle-free vaccine formulations utilizing GeoVax’s… read more

• Enesi Pharma and Sementis sign R&D Collaboration focused on Needle-free Solid Dose Vaccines for Peanut Allergy and chikungunya/Zika Infection

  5th November 2018

  Oxford, UK and Melbourne, Australia – 5 November 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, and Sementis, a biotechnology company developing innovative vaccine candidates for the prevention of allergies and infectious diseases, announce they have entered into a collaborative agreement. The collaboration is focused on the development… read more

• Enesi Pharma Selected to Showcase Unique ImplaVax® Needle-Free Solid Dose Vaccine Platform in Inaugural ‘Lightning Talk’ Session at BARDA Industry Day

  16th October 2018

  Oxford, UK – 16 October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, is honoured to have been selected to present a ‘Lightning Talk’ at The Biomedical Advanced Research and Development Authority (BARDA) Industry Day on 29-30 October at the Grand Hyatt in Washington DC, U.S.   BARDA is a key… read more

• Enesi Pharma to showcase unique ImplaVax® Needle-Free Solid Dose Vaccine Platform at World Vaccine Congress Europe 2018

  4th October 2018

  Oxford, UK – 4 October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, announces it will showcase its innovative ImplaVax® needle-free solid dose vaccine platform at the upcoming World Vaccine Congress Europe 2018 in Lisbon, Portugal (29-31 October 2018). Enesi Pharma is once again a Silver Sponsor of… read more

• Enesi Pharma and Public Health England Enter R&D Collaboration for Novel Needle-Free Solid-Dose Vaccine for Emergent Threat Pathogens

  1st October 2018

  Oxford, UK – 1st October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces it has entered a research and development collaboration with Public Health England (PHE), an executive agency of the UK Government’s Department of Health and Social Care.  The collaboration is focused on the development and evaluation… read more

• Enesi Pharma and Walter Reed Army Institute of Research (WRAIR) sign Cooperative R&D Agreement (CRADA) for Needle-Free Solid-Dose Vaccine for Shigella Infection

  24th September 2018

  Oxford, UK – 24th September 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces it has entered a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR), a United States Department of Defense Laboratory, regarding Shigella vaccine development. The CRADA is focused on… read more

• Enesi Pharma Drives Forward Growth Plans with Move to New State-Of-The-Art Headquarters in Oxford

  20th September 2018

  Oxford, UK – 20th September 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce the opening of its new headquarters including state-of-the-art research and development facilities in Milton Park, Oxford, in the heart of the UK’s dynamic life science cluster.  Since its launch in 2017… read more

• Enesi Pharma Welcomes Global Vaccine Expert James Cheyne to its Scientific Advisory Board

  3rd September 2018

  Oxford, UK – 3 September 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces the appointment of James Cheyne to its Scientific Advisory Board (SAB). Enesi’s SAB comprises experts in vaccines and preventative health from leading academic, research and international health organisations across the US and Europe. Mr Cheyne… read more

• Enesi Pharma presenting at the World Vaccine Congress, Washington – Wednesday 4 April 2018

  29th March 2018

  Enesi Pharma are attending the World Vaccine Congress, Washington 3-5 April 2018. David Hipkiss, CEO, will be presenting  our latest developments in the Viral Vectors & Novel Platforms Technology Showcase entitled ImplaVaxTM , Unique needle free solid dose vaccine platform delivering enhanced immunogenicity with ultimate convenience and no cold chain at 10.25am on Wednesday, in Ballroom level… read more

• Enesi Pharma appoints new international Scientific Advisory Board

  6th November 2017

  Oxford, UK – 6 November 2017. Enesi Pharma, a clinical-stage company developing unique injectable solid dose drug-device combination products, announces the formation of a new International Scientific Advisory Board (SAB). The SAB includes experts in vaccines and preventative health from leading academic/ research and international health organisations in the US and Europe. Commenting on the… read more

• Enesi Pharma debuts at World Vaccine Congress

  5th October 2017

  Oxford, UK – 10 October 2017. Enesi Pharma, a clinical-stage company developing unique injectable solid dose drug-device combination products, announces its launch as a new company at the World Vaccine Congress, which takes place on 10-12 October in Barcelona, Spain. Enesi is focused on the development of innovative vaccines and therapeutics using its proprietary ImplaVax™… read more